SORILUX Drug Patent Profile
✉ Email this page to a colleague
When do Sorilux patents expire, and what generic alternatives are available?
Sorilux is a drug marketed by Mayne Pharma and is included in one NDA. There are two patents protecting this drug.
This drug has twenty-nine patent family members in thirteen countries.
The generic ingredient in SORILUX is calcipotriene. There are twelve drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the calcipotriene profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sorilux
A generic version of SORILUX was approved as calcipotriene by FOUGERA PHARMS on May 6th, 2008.
Summary for SORILUX
| International Patents: | 29 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 51 |
| Clinical Trials: | 5 |
| Patent Applications: | 5,629 |
| Drug Prices: | Drug price information for SORILUX |
| What excipients (inactive ingredients) are in SORILUX? | SORILUX excipients list |
| DailyMed Link: | SORILUX at DailyMed |
Recent Clinical Trials for SORILUX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Skin Sciences, PLLC | Phase 4 |
| Mayne Pharma International Pty Ltd | Early Phase 1 |
| Tulane University | Early Phase 1 |
Pharmacology for SORILUX
| Drug Class | Vitamin D Analog |
US Patents and Regulatory Information for SORILUX
SORILUX is protected by five US patents.
Patents protecting SORILUX
Vitamin formulation
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
Vitamin formulation
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER
Vitamin formulation
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
Vitamin formulation
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER
Vitamin formulation
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | SORILUX | calcipotriene | AEROSOL, FOAM;TOPICAL | 022563-001 | Oct 6, 2010 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Mayne Pharma | SORILUX | calcipotriene | AEROSOL, FOAM;TOPICAL | 022563-001 | Oct 6, 2010 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SORILUX
See the table below for patents covering SORILUX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | E381315 | ⤷ Try a Trial | |
| Spain | 2299258 | ⤷ Try a Trial | |
| New Zealand | 563560 | Vitamin formulation for treating a dermatological skin disorder | ⤷ Try a Trial |
| Austria | 381315 | ⤷ Try a Trial | |
| Canada | 2333869 | COMPOSITION DE MOUSSE (MOUSSE COMPOSITION) | ⤷ Try a Trial |
| Canada | 2611147 | PREPARATION VITAMINEE (VITAMIN FORMULATION) | ⤷ Try a Trial |
| Spain | 2431330 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
